Biogen
NEWS
In a Bloomberg News survey of 25 large insurers, none described the drug as “medically necessary,” and said Aduhelm was still experimental.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative trend vote on the company’s Marketing Authorization Application for Aduhelm.
Biogen announced that after 23 years with the company, Alfred W. Sandrock Jr. will retire on Dec. 31. Sandrock had his hand in the development of multiple treatments for neurological diseases.
Thanks partly to Biogen’s pricey new Alzheimer’s drug, Medicare enrollees will be burdened with higher monthly premiums for their Part B coverage.
President Joe Biden has nominated former U.S. Food and Drug Administration Commissioner Robert Califf to reprise his role at the agency’s helm.
It was another busy week for clinical trial news. Here’s a look.
Boston-based Biogen shared data from two Phase III studies at the Clinical Trials on Alzheimer’s Disease conference that showed the latest efficacy data of Aduhelm (aducanumab).
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease.
JOBS
IN THE PRESS